Multiple Signaling Pathways Converge to Regulate Bone-Morphogenetic-Protein-Dependent Glial Gene Expression

Justin J. Dore  John C. DeWitt  Nithya Setty  Mareshia D. Donald  Esther Joo  Melissa A. Chesarone  Susan J. Birren

Department of Biology and Volen National Center for Complex Systems, Brandeis University, Waltham, Mass., USA

Key Words
Neural crest · GFAP · BMP2 · Kinase pathways · Glial differentiation

Abstract
A fundamental problem in developmental neuroscience is understanding how extracellular cues link to complex intracellular signaling pathways to drive stage-specific developmental decisions. During the formation of the mammalian peripheral nervous system, bone morphogenetic proteins (BMPs) promote neuronal differentiation. BMPs also maintain the expression of early glial genes such as GFAP, while blocking the acquisition of a mature, myelinating Schwann cell phenotype. We investigated the BMP-activated signaling pathways that contribute to early glial gene expression to address the question of how specific signaling interactions contribute to cell fate decisions in neural crest lineages. Using a neural-crest-derived cell line that exhibits the characteristics of immature Schwann cells, we found that BMP2 promotes GFAP expression using Smad signaling as well as the phosphoinositide-3 kinase (PI3K) and mitogen-activated protein kinase1/2extracellular signal-regulated kinase-(MEK1/2/ERK) pathways. The GFAP promoter does not contain known Smad consensus sites, suggesting that Smads may act indirectly to promote GFAP expression. We provide evidence that this indirect effect may be mediated via induction of immediate early genes and the transcription factor Sp1 by demonstrating that these transcriptional regulators are induced by BMP2 and contribute to GFAP promoter activity. These findings demonstrate new roles for intracellular kinase pathways in mediating the effects of BMPs during the early stages of glial differentiation and suggest that differential contributions by signaling and transcriptional networks may contribute to the range of effects of BMPs on neuronal and glial development during the formation of the peripheral nervous system.

Introduction
Bone morphogenetic proteins (BMPs) influence many developmental processes including osteogenesis [1], cardiac [2] and neural development [3]. During formation of the central nervous system, BMPs influence both glial and neuronal differentiation. BMPs promote commitment to an astroglial fate among neural progenitor cells derived from embryonic cortex [4], promote astrocytic maturation of GFAP-positive neural progenitor cells [5],
and increase development of the astrocytic lineage in vivo [6]. In addition to these positive effects on astrocytic development, BMPs also negatively regulate the maturation of oligodendrocytes [7, 8], the myelinating cells of the central nervous system, by preventing their differentiation and driving early oligodendrocytes to acquire astrocytic properties [9, 10]. Thus, BMP signaling has complex roles in determining the numbers of different cell types within neural lineages.

BMPs also regulate peripheral nervous system (PNS) development by promoting neuron formation in both the neural crest [11, 12] and in postmigratory sensory [13], sympathetic and enteric ganglia [3, 14–17]. Interestingly, BMPs also appear to promote the early stages of peripheral glial development while blocking the acquisition of mature myelinating properties. BMP2 promotes GFAP expression in a neural-crest-derived cell line, but prevents gene expression changes that mark the later stages of glial development [18]. This suggests there are multiple roles for BMPs during PNS formation and raises the question of how BMP signaling drives distinct developmental events in different neural lineages.

One way for BMPs to exert cell-type-specific effects during development is to maintain distinct, intracellular signaling pathways. Signaling via Smad proteins represents the canonical pathway utilized by both BMPs (Smads 1/5/8) and TGF-β (Smads 2/3). Additional evidence suggests that non-Smad-associated kinase cascades also contribute to signaling by TGF-β family members [19–22]. Non-Smad pathways utilized by BMP2 include Ras/Raf/ERK [23–25] and phosphoinositide-3 kinase (PI3K)/protein kinase B (PKB/Akt) [2, 26, 27]. Interactions with non-Smad kinase pathways can have tissue-specific positive or negative effects on Smad-mediated TGF-β family signaling. For example, a direct physical interaction with PKB prevents Smad3 nuclear translocation in a hepatocyte cell line treated with TGF-β [28]. Conversely, ERK activity promotes Smad activation in response to TGF-β in human mesangial cells [29]. Thus, a variety of conditions influence the output of BMP signaling pathways, including the cell or tissue type, and possibly the developmental stage. The pathways that contribute to cell fate decisions during early glial development remain to be identified, but a better understanding of the intracellular effectors used by BMPs will help to explain how BMPs exert different effects on distinct PNS lineages.

We previously demonstrated that PI3K, MEK1/2/ERK and Smad signaling contribute to the BMP-dependent induction of the early glial gene GFAP in a neural-crest-derived cell line [18]. We have now examined the interactions between these signaling pathways and have defined the transcriptional requirements of BMP2-dependent GFAP expression using both the GFAP promoter and a promoter consisting of Smad consensus sites. We demonstrate that PI3K and MEK1/2/ERK signaling contributes to glial gene activity in response to BMP treatment and may regulate cytosolic Smad1 phosphorylation and nuclear transport dynamics in this neural-crest-derived cell line. In addition, activation of BMP signaling pathways results in the selective induction of several immediate early genes and the transcription factor Sp1. We define a regulatory role for Sp1 and AP1 sites within the GFAP promoter and suggest a mechanism by which BMPs may influence the early steps of differentiation in glial lineages. Together, these data indicate that the regulation of GFAP expression by BMP2 results from both transcriptional and nontranscriptional mechanisms, and suggest that BMP2 utilizes combinations of different downstream effectors [30, 31] that may contribute to the regulation of lineage-specific gene expression during nervous system development.

**Materials and Methods**

**Plasmid Constructs**

The rat GFAP promoter construct containing 1.9 kb of upstream promoter sequence directionally subcloned into the pGL3 basic vector (Promega) was kindly provided by Dr. C.E. Finch [32]. A Smad binding element (pSBE) construct containing four tandem repeats of the Smad-responsive sequence CAGACA [33] was provided by Dr. James West (UCHSC). For signal transduction assays, cells were transfected or co-transfected with dominant negative (DN) Ras (S17N) and/or DN pcDNA-PKB (T308A, S473A) (DN PKB) [34] driven by the Mouse Stem Cell Virus (MSCV) promoter provided by Dr. R. Ren and/or DN pcDNA-PKB (T308A, S473A) (DN PKB) [35] (a gift of Dr. Maria Alexander-Bridges) or DN Smad1 (2SA) (DN Smad1) [36] (a gift of Dr. Steven Harris). Dominant negative pCMV5-Smad5 (DN Smad5) (Addgene, Cambridge, Mass., USA) was generated by substituting serine [36] for glycine 419. All constructs were co-transfected with Renilla luciferase under constitutive control of the pRL-thymidine kinase promoter (Promega) to control for transfection efficiency. All values are represented as arbitrary relative light units of control and BMP-activated values or as fold increase over the control condition.

**Site-Directed Mutagenesis**

Substitution mutations of putative transcription factor binding sites in the GFAP promoter were generated using the Quick-Change Site Directed Mutagenesis kit (Stratagene) according to the manufacturer’s instructions. Base pair changes were generated in the pGL3b-GFAP AP1 or Sp1 binding sites. The ΔSp1 base pair changes were: GGGGCGGG to GGTATAGG. The ΔAP1 base pair changes were: TGACCATTA to TGGTGTTA. Primers
were designed using PrimerX software (bioinformatics.org/prim-erx/documentation.html). Mutations were confirmed by sequencing using CEQ Dye Terminator Cycle Sequencing (DTCS) (Beckman Coulter, Fullerton, Calif., USA) at the Brandeis Biochemistry Sequencing Core Facility or by GeneWiz, South Plainfield, N.J., USA.

**Cell Culture and Transient Transfection**

Neural-crest-derived, v-my-c immortalized cells (NCM1) [37] were cultured on fibronectin-coated dishes (1 mg/ml) in 2x MAH medium [38] containing L15CO₂ [39], 10% FBS, fresh vitamin mix (FVM) and penicillin/streptomycin/glutamine (1:1:2). Cells were maintained under standard tissue culture conditions at 37°C, 5% CO₂. Recombinant BMP2 (Wyeth Pharmaceuticals, Cambridge, Mass., USA) was diluted in medium and used to grow cells to about 85% confluence in 24-well, fibronectin-coated tissue culture dishes (Corning). Twenty-four hours before transfection, cells were plated at a density of 40,000 cells/well in 2x MAH media and grown to about 85% confluence in 24-well, fibronectin-coated tissue culture dishes (Corning). Twenty-four hours before transfection, cells were plated in serum-free medium consisting of L15CO₂, 1% BSA, FVM and 1:1:2. Transfections used the Lipofectamine method according to the manufacturer’s instructions (Invitrogen). GFAP-luciferase (0.5 μg) or pSBE-luciferase (0.5 μg) constructs were added with the Renilla luciferase construct (0.25 μg). Where indicated, reporter constructs were cotransfected with 0.5 μg of DN Ras, DN PKB, DN S1 or DN S5. Additional constructs encoding the full-length GFAP promoter with mutations in the putative Sp1 site, AP1 site or both sites (see above) were also transfected. Five hours after transfection, 10 ng/ml BMP2 was added to select wells and the cells were harvested 24 h later. Where indicated, all kinase inhibitors were added to cultures 45 min prior to BMP2 treatment at the following concentrations: PD98,059 (10 μM), U0126 (10 μM) and LY294,002 (10 μM). All transfections were performed in triplicate in a minimum of five independent experiments. At the end of the experiment, cells were lysed and assayed for luciferase activity using the Dual Reporter Assay System (Promega).

**Western Blot Analysis**

NCM1 cells were treated with 10 ng/ml of BMP2 for 0, 15 min, 45 min, 1.5 or 5 h for protein analysis. Cells were then lysed and whole-cell lysates used for immunodetection of Sp1 and AP1 protein expression. For nuclear and cytoplasmic immunoblotting, cells were serum-starved for 24 h prior to BMP2 treatment at the following concentrations: PD98,059 (10 μM), U0126 (10 μM) and LY294,002 (10 μM). All transfections were performed in triplicate in a minimum of five independent experiments. At the end of the experiment, cells were lysed and assayed for luciferase activity using the Dual Reporter Assay System (Promega).

**Comparative RT-PCR**

RT-PCR was performed as previously described [16]. RNA was isolated using an RNeasy mini kit (Qiagen) from cells cultured in serum-free media, from BMP2-treated cells after 0, 15 min, 1, 6, 12, or 24 h, from cells treated with BMP2 following kinase inhibitor treatment, or from cells treated with BMP2 for 24 h in the presence or absence of cycloheximide. RNA was reverse-transcribed using MMLV Reverse Transcriptase (Invitrogen). G3PDH primers were run in triplicate in each individual experiment to match cDNA amounts. All PCRs were performed in triplicate and run on 1.4% agarose gels with 0.5 μg/ml ethidium bromide. Bands were quantified on a GelDoc system (BioRad) using Molecular Analyst Software (version 2.1.2) and normalized using G3PDH triplicate averages for treated or control samples. Primer sequences were designed using the Whitehead Institute Genome Center Primer3 program [40]. Expression levels of Sp1, c-fos, fos-B, FRA1, Jun-D, and Jun-B are expressed relative to G3PDH and values shown are averages ± SEM from three or more independent experiments. The following primer sequences were used:

- **Sp1:** 5’TATAGAAAGAGTGGGGCAAC-3’ and 5’-AGGTGT-ATTGTCTTGTCCTTGG-3’
- **c-fos:** 5’-AGAGCGGAGGTGGTAAGAC-3’ and 5’-ATTGGAGGAGGCTGA-3’
- **Fos-b:** 5’-GGGAACTTGGCACCTCTGTC-3’ and 5’-TGGCTAAAGGGGATAAGCA-3’
- **FRA1:** 5’-GCGAAGACCAAAAGAAGA-3’ and 5’-TGGAGAAAGGAGTACAAGG-3’
- **FRA2:** 5’-GCTCTGTGTCTCAAGGGATTG-3’ and 5’-ACTGTTCCACACTGTACTG-3’
- **Jun-D:** 5’-TGGAGGAGAAGACCGAGTG-3’ and 5’-ACGGACAGAGATGTGGGACT-3’
- **Jun-B:** 5’-AGGCAAGGTGGAAGACCTCAAG-3’ and 5’-AGTCACCAACACAAAACATC-3’
- **G3PDH:** 5’-ACACACACACAAACACATC-3’

**Statistics**

Significance was calculated using analysis of variance (ANOVA) followed by Fisher’s Projected Least Significant Difference post hoc analysis on StatView software, version 4.5 (Abacus Concepts).

**Results**

**Smads Regulate Both pSBE and GFAP Promoter Activity**

We investigated the requirements for Smad signaling in the activation of the GFAP promoter using DN Smad proteins (DN Smad1 and DN Smad5) and the GFAP promoter [32] to drive luciferase expression in NCM1 cells. NCM1 cells are a neural-crest-derived cell line with the properties of a committed glioblastoma cell line [16]. RNA was isolated using an RNeasy mini kit (Qiagen) from cells cultured in serum-free media, from BMP2-treated cells after 0, 15 min, 1, 6, 12, or 24 h, from cells treated with BMP2 following kinase inhibitor treatment, or from cells treated with BMP2 for 24 h in the presence or absence of cycloheximide. RNA was reverse-transcribed using MMLV Reverse Transcriptase (Invitrogen). G3PDH primers were run in triplicate in each individual experiment to match cDNA amounts. All PCRs were performed in triplicate and run on 1.4% agarose gels with 0.5 μg/ml ethidium bromide. Bands were quantified on a GelDoc system (BioRad) using Molecular Analyst Software (version 2.1.2) and normalized using G3PDH triplicate averages for treated or control samples. Primer sequences were designed using the Whitehead Institute Genome Center Primer3 program [40]. Expression levels of Sp1, c-fos, fos-B, FRA1, Jun-D, and Jun-B are expressed relative to G3PDH and values shown are averages ± SEM from three or more independent experiments. The following primer sequences were used:

- **Sp1:** 5’TATAGAAAGAGTGGGGCAAC-3’ and 5’-AGGTGT-ATTGTCTTGTCCTTGG-3’
- **c-fos:** 5’-AGAGCGGAGGTGGTAAGAC-3’ and 5’-ATTGGAGGAGGCTGA-3’
- **Fos-b:** 5’-GGGAACTTGGCACCTCTGTC-3’ and 5’-TGGCTAAAGGGGATAAGCA-3’
- **FRA1:** 5’-GCGAAGACCAAAAGAAGA-3’ and 5’-TGGAGAAAGGAGTACAAGG-3’
- **FRA2:** 5’-GCTCTGTGTCTCAAGGGATTG-3’ and 5’-ACTGTTCCACACTGTACTG-3’
- **Jun-D:** 5’-TGGAGGAGAAGACCGAGTG-3’ and 5’-ACGGACAGAGATGTGGGACT-3’
- **Jun-B:** 5’-AGGCAAGGTGGAAGACCTCAAG-3’ and 5’-AGTCACCAACACAAACACATC-3’
- **G3PDH:** 5’-ACACACACACAAACACATC-3’

**Statistics**

Significance was calculated using analysis of variance (ANOVA) followed by Fisher’s Projected Least Significant Difference post hoc analysis on StatView software, version 4.5 (Abacus Concepts).
ciferase) that contains tandem repeats of the Smad consensus sequence CAGACA. BMP2 treatment of GFAP-luciferase-expressing NCM1 cells resulted in a four-fold induction (fig. 1a). DN Smad1 did not significantly inhibit this BMP2-induced GFAP promoter activity. DN Smad5 and the combination of DN Smad1 with DN Smad5 led to a partial but significant reduction in BMP2-dependent GFAP expression (fig. 1a). In contrast to the GFAP-luciferase construct, BMP2 treatment resulted in a robust 20-fold induction of the pSBE promoter. Inhibition of the BMP2 response was significant for either DN Smad1 or DN Smad5 alone, with almost complete inhibition resulting from combined transfection of the two DN constructs (fig. 1b). This suggests that Smads contribute to the regulation of the early glial gene GFAP, but cannot account fully for the BMP-dependent regulation of this promoter.

**PKB and Ras Influence Both GFAP and pSBE Promoter Activity**

We previously demonstrated that pharmacological inhibition of both PI3K and MEK1/2/ERK resulted in a significant decrease in BMP-induced GFAP promoter activation [18]. We have now investigated the promoter specificity of these non-Smad kinase pathways by comparing the requirement for the PI3K and MEK1/2/ERK pathways in the activation of the GFAP and the Smad consensus-containing SBE promoter (fig. 2). We measured BMP2 responses in cells expressing DN signaling proteins in the PI3K and MEK1/2/ERK pathways. NCM1 cells were transfected with the pSBE promoter-luciferase construct and/or DN Ras to target the MEK1/2/ERK pathway, and/or DN protein kinase B (PKB, Akt) to target PI3K signaling [42] (fig. 2a, c). These DN constructs have been used extensively to effectively inhibit signaling from these pathways in a variety of systems [43–46]. Inhibition of the PI3K pathway with DN PKB, or coexpression of DN PKB with DN Ras, resulted in a significant reduction in BMP2-dependent activity at the Smad consensus pSBE promoter whereas DN Ras alone had no effect (fig. 2a). To further confirm the involvement of the PI3K pathway in pSBE promoter activation, we also used pharmacological inhibitors of these pathways. Again, a significant reduction in BMP2-dependent pSBE activity was observed only in conditions in which PI3K was inhibited (fig. 2b), suggesting that the PI3K pathway plays a role in promoting the activity or availability of Smad interactions at the pSBE elements.
Fig. 2. Protein kinase B (PKB) signaling contributes to BMP2 induction of the GFAP and the pSBE promoters. a NCM1 cells were transfected with the pSBE promoter-luciferase construct in addition to constructs encoding DN Ras and/or DN PKB. Cotransfection of pSBE with DN Ras did not reduce pSBE promoter activity following BMP2 treatment. Cotransfection of DN PKB, or DN PKB with DN Ras led to statistically significant (* p < 0.05, ** p < 0.01) reductions in BMP2-stimulated pSBE activity. b NCM1 cells were cotransfected with the pSBE construct and treated with 10 ng/ml BMP2 for 24 h following a 45-min pretreatment with PD98,059 (10 μM) or UO126 (10 μM), inhibitors of MEK1/2/ERK or the PI3K inhibitor LY294,002 (10 μM). pSBE transcriptional activity, as measured by the luciferase assay, was significantly decreased (** p < 0.01) only when PI3K was inhibited. Results represent the averages ± SEM from 5 or more independent experiments conducted in triplicate. c GFAP-luciferase was transfected with DN constructs as in a. DN Ras did not affect GFAP promoter activity in response to BMP2, while DN PKB showed a trend that was not significant towards decreased GFAP transcriptional activity. Cotransfection of GFAP with both DN Ras and DN PKB led to a statistically significant (* p < 0.05) decrease in GFAP transcriptional activity following BMP2 treatment. Results are the averages ± SEM of 4 or more independent experiments performed in triplicate and normalized to control values. d To confirm expression of transfected constructs, NCM1 cells were transfected with GFP-tagged DN Ras, Flag-tagged DN Smad1 or Smad5, DN PKB or left untransfected. Cells were fixed after 24 h and staining was performed using an anti-GFP antibody to recognize DN Ras, anti-Flag to recognize DN Smad1 or Smad5, or an antibody recognizing total PKB. Expression of DN PKB was inferred by the cytoplasmic, punctate staining for PKB seen in transfected cells (box labeled DN) that was not seen in nontransfected cells.
We also examined the effect of the DN proteins on BMP2 induction of the GFAP promoter. The DN PKB did not have a significant effect on the BMP2 induction of the GFAP promoter, although there was a noticeable trend toward decreased activity (fig. 2c). This may reflect the same regulation of Smad interactions as seen for the SBE promoter, with the smaller effect accounted for by the limited role for Smads in GFAP induction (fig. 1). Inactivation of the Ras pathway with DN Ras had no effect on BMP2-dependent GFAP activity, but interestingly, co-transfection of both DN PKB and DN Ras significantly reduced BMP2-induced activation of the GFAP promoter (fig. 2c). This suggests that the Ras pathway may collaborate with PI3K signaling to mediate the BMP response and supports our previous findings using pharmacological inhibitors of these pathways [18]. Expression of transfected constructs was confirmed using immunostaining against Ras-GFP, flag-tagged Smad1 or Smad5, DN PKB or endogenous PKB (fig. 2d).

---

**Inhibition of PI3K and Ras Alters Smad Phosphorylation Patterns**

One way that kinase pathways could affect activity at Smad-sensitive promoters is by influencing Smad phosphorylation or nuclear localization. We previously demonstrated that BMP2 treatment of NCM1 cells resulted in movement of Smad1 to the nucleus [18]. We therefore examined the effect of PI3K and MEK1/2/ERK kinases in regulating BMP2-dependent Smad dynamics by using Western analysis to examine phospho-Smad (P-Smad) localization in cytoplasmic and nuclear fractions. NCM1 cultures were treated with or without BMP2 in the presence or absence of pharmacological inhibitors of the PI3K (LY294,002) and MEK1/2/ERK (PD98,059) pathways. Western blots were probed with antibodies recognizing phospho-Smad1/5/8 (P-Smad1/5/8) (fig. 3a). Top panel shows P-Smad1/5/8, β-Actin was used as a loading control (bottom). b Quantification of normalized phosphorylated-Smad1/5/8 values from three independent immunoblotting experiments. Inhibition of kinase pathways led to a significant decrease in the cytosolic pool of phosphorylated Smads (* p < 0.05) with no effect on the amount of phosphorylated Smads in the nucleus.

---

**Fig. 3.** Inhibition of PI3K and MEK1/2/ERK pathways reduces cytosolic phosphorylated-Smad1/5/8. NCM1 cells were treated or not with inhibitors of the PI3K and MEK1/2/ERK pathways followed by BMP2 exposure for 30 min. Cytoplasmic and nuclear fractions were extracted and immunoblotting performed against phosphorylated-Smad1/5/8 (P-Smad1/5/8) (a). Top panel shows P-Smad1/5/8, β-Actin was used as a loading control (bottom). b Quantification of normalized phosphorylated-Smad1/5/8 values from three independent immunoblotting experiments. Inhibition of kinase pathways led to a significant decrease in the cytosolic pool of phosphorylated Smads (* p < 0.05) with no effect on the amount of phosphorylated Smads in the nucleus.
Signaling Pathways Contributing to BMP-Induced GFAP Activity

partments following a 30-min treatment. Smad phosphorylation takes place in the cytoplasm, thus the nuclear localization confirms that nuclear translocation takes place following BMP2 treatment. There was a significant decrease in the level of cytoplasmic P-Smad in the presence of the kinase inhibitors. Interestingly, this same treatment had little effect on the level of nuclear P-Smads. These data suggest that the PI3K and/or the MEK1/2/ERK pathways promote early Smad phosphorylation, which, over time, could contribute to BMP2-mediated transcriptional responses.

Regulation of Endogenous GFAP Expression

Since PI3K and MEK1/2/ERK signaling contribute to the BMP2-dependent activity of the GFAP promoter in a luciferase reporter system, we went on to ask whether these pathways are important for regulating expression of the endogenous GFAP gene. NCM1 cells were treated for 24 h with BMP2 in the absence or presence of increasing concentrations of the PI3K inhibitor LY294,002 and the MEK1/2 inhibitor PD98,059. Previous experiments demonstrated that these inhibitor concentrations were not toxic to NCM1 cells [18]. BMP2 led to a robust induction of endogenous GFAP mRNA (fig. 4a) and the kinase inhibitors reduced this expression in a dose-dependent manner.

Given the absence of Smad consensus sites in the GFAP promoter, we asked whether indirect effects involving activation of other genes contribute to the induction of the endogenous GFAP promoter by BMP2. We treated NCM1 cells with the translational inhibitor cycloheximide (CHX) to determine if there was a requirement for de novo protein synthesis in regulating GFAP expression in response to BMP2. In the absence of the inhibitor, BMP2 significantly induced GFAP mRNA. Addition of 100 ng/ml of CHX reduced BMP induction of GFAP to control levels (fig. 4b), suggesting a requirement for new protein synthesis in the BMP-dependent regulation of the GFAP promoter.

BMP2 Selectively Regulates Immediate Early Genes in NCM1 Cells

One mechanism by which BMPs could act indirectly to promote GFAP expression would be to induce immediate early genes that would act at GFAP promoter sites. BMPs use both Sp1 and immediate early genes that comprise the AP1 complex to regulate gene expression and tissue-type differentiation during development [48–50], and we have recently identified Sp1 and AP1 consensus sequences within the region of the GFAP promoter required for BMP induction [18]. We therefore asked whether Sp1 and immediate early genes were regulated by BMP2 by examining the expression of mRNAs for multiple immediate early genes and the transcription factor Sp1 in NCM1 cells. BMP2 treatment over 24 h did not alter expression of JunB or Fra2 mRNA (fig. 5a). Over the same period, c-Jun and fosB mRNA levels decreased modestly (fig. 5b). In contrast, Sp1 mRNA levels rose steadily over

Fig. 4. BMP2-dependent regulation of endogenous GFAP expression involves PI3K and Ras signaling pathways and requires protein synthesis. a NCM1 cells were treated with the PI3K inhibitor LY294,002 (LY) and the MEK1/2/ERK inhibitor PD98,059 (PD). Addition of 10 ng/ml BMP2 led to robust induction of GFAP mRNA after 24 h that was reduced in a dose-dependent manner by the PI3K and MEK1/2 inhibitors. b To determine if protein synthesis was required for BMP-dependent GFAP activity, NCM1 cells were treated with BMP2 in the presence or absence of the translational inhibitor cycloheximide (CHX, 100 ng/ml). BMP2 led to a significant increase in GFAP expression (** p < 0.001) that was abolished by cyclohexamide treatment.
the 24-hour treatment period, increasing approximately 3-fold compared to control conditions while Fra1 peaked after 6 h with a subsequent decline in expression (fig. 5c). JunD mRNA increased significantly at 1 h then steadily declined until 24 h (fig. 5d). Interestingly, c-fos mRNA levels did not begin to increase until 6 h after BMP2 addition and then increased more than 3-fold between 6 and 24 h (fig. 5d). These data suggest that BMP2 initiates a complex pattern of gene expression with both early and late expression of immediate early genes.

Given the presence of the Sp1 consensus site in the GFAP promoter and the increased expression of Sp1 mRNA, we used Western analysis to examine changes in the level of Sp1 protein over the 24-hour time course and compared it to the induction of GFAP protein over the same period (fig. 6a). Quantification across multiple experiments showed that Sp1 protein significantly increased following a 6-hour exposure to BMP2 (fig. 6b). This demonstrates a lag between mRNA induction and protein induction, since a significant increase in Sp1 mRNA was seen after 1 h of treatment with a return to baseline levels after 24 h (d) (*p < 0.05, **p < 0.01, ***p < 0.001).
ment (fig. 6c). While the initial increase in GFAP protein level was correlated with the initial rise in Sp1 protein, GFAP protein remained high, even after Sp1 levels decreased. Thus, the induction and maintenance of GFAP by BMPs may involve temporal changes in the expression patterns of additional immediate early genes such as Fra1, JunD and possibly c-fos in addition to the transcription factor Sp1.

**Contribution of AP1 and Sp1 to GFAP Activation**

We previously identified adjacent AP1 and Sp1 consensus sites within a 500-bp region of the GFAP promoter required for BMP2-mediated induction (fig. 7a) [18]. Since BMP2 induced expression of transcription factors that bind to these sites, we investigated whether these interactions contributed to the regulation of the GFAP promoter. We performed site-directed mutagenesis of the GFAP promoter (fig. 7b) followed by analysis of basal and BMP2-induced activity of the wild type, AP1 and Sp1 mutants, or a double mutant using luciferase assays. Mutation of the Sp1 site resulted in a significant increase in the basal, uninduced activity of the promoter (fig. 7c). Promoter activity was even greater following BMP2 treatment, although there was a small decrease in the fold induction compared to the control construct (fold induction: GFAP-Luc 2.87 ± 0.15-fold; ΔSp1GFAP-Luc 2.22 ± 0.12-fold; ΔSp1GFAP-Luc significantly different from GFAP-Luc, p < 0.01). We did not observe a significant increase in baseline activity for the adjacent AP1 site mutation, although induction with BMP2 indicates the presence of additional activator sites in the GFAP promoter. These data suggest that a transcriptional repressor normally occupies the Sp1 site and that mutation of the Sp1 site prevents repressor binding and increases basal activity, possibly due to increased availability of the adjacent AP1 site. Displacement of this repressor may involve increased levels of Sp1 protein following BMP2 treatment, permitting GFAP transcriptional activation from activator sites that might include the normally occluded AP1 site.

**Fig. 6.** BMP2 regulates GFAP and Sp1 protein expression. NCM1 cells were treated with BMP2 for the indicated times and whole-cell lysates extracted and immunoblotted using Sp1 or GFAP polyclonal antibodies. C = Control. **a** Representative immunoblots showing changes in Sp1 and GFAP protein over the course of 24 h of BMP2 treatment. **b** Sp1 protein expression increased following BMP2 treatment, peaking at 6 h followed by a steady decline to baseline levels (a p < 0.05 compared to control, b p < 0.05 compared to 6 h). **c** GFAP protein increased 2-fold following BMP2 treatment for 12 h and remained elevated at 24 h (p < 0.05). Graphs show the averages of 4 independent immunoblotting experiments ± SEM for each protein analyzed using ANOVA. All values were normalized using β-actin as a loading control.
While the Sp1 mutation increases basal activity, this increase is not seen for the Sp1, AP1 double mutant. In the absence of both functional Sp1 sites and AP1 sites, there is no longer any repression or activation from those sites, permitting induction by way of BMP-dependent activation of additional site(s). This suggests that while the increase in Sp1 protein following BMP2 treatment plays a role in displacing a repressor protein(s), in the absence of repressor binding, induction is effectively mediated via other promoter sites (fig. 8). Thus, these sites contribute to a dynamic regulation of repressors and activators that mediates basal and BMP-dependent activation of the GFAP promoter.

**Discussion**

One way to understand the differing effects of BMPs on neuronal and glial development is to define the intracellular pathways that are involved in cell-specific gene expression. We have examined the consequences of BMP signaling on the expression of a glial-specific gene in a peripheral glial cell line and shown that the PI3K and MEK1/2/ERK pathways, in addition to the canonical Smad pathway, contribute to induction of the GFAP promoter by BMP2. Comparison of the complex GFAP promoter to a promoter consisting solely of Smad
Consensus sites [33] has shown that Smad and non-Smad pathways contribute differentially to the BMP-dependent activity. We show that BMP-dependent gene expression is regulated at multiple levels that include kinase-dependent regulation of cytoplasmic Smad activation, regulation of immediate early gene expression, and promoter interactions. These findings contribute to a growing body of evidence that identifies a diverse range of downstream effectors for BMPs and other TGF-β family members [2, 26, 27, 29, 51–53]. The timing and correct balance of activation of these pathways are likely to determine critical developmental decisions including the regulation of peripheral neuronal and glial cell fates.

BMP receptor activation leads to nuclear accumulation of phosphorylated Smad1/5 and assembly of an active promoter complex consisting of Smads and associated transcriptional activators [54]. Thus, it was not surprising that BMP2 strongly induced the activity of a synthetic promoter consisting of repeated Smad consensus sites [32, 33]. BMP2 also induced activity of the glial-specific GFAP promoter despite a lack of known Smad consensus sites within the sequence [18]. This suggested either an indirect effect of Smads, or the actions of a Smad-independent pathway in the BMP-dependent regulation of the GFAP promoter. Inhibition of Smad signaling via expression of DN Smad proteins resulted in a partial, but significant reduction in BMP-induced activity at the GFAP promoter, suggesting that both of these mechanisms, indirect effects of Smad activation and Smad-independent signaling, contribute to activation. In contrast, inhibition of Smad signaling resulted in the almost complete inhibition of BMP2-dependent activation of the pSBE promoter, demonstrating that Smad signaling can differentially contribute to the activity of different BMP responsive promoters.

Intracellular kinases are known effectors of BMP signaling in a number of systems and may act to modulate the effects of BMPs in a cell type-specific manner [2, 23–25, 27]. We found that the PI3K and MEK1/2/ERK pathways promoted BMP signaling in our peripheral glial cell line for both the Smad-binding pSBE and the GFAP promoters. Recent studies have demonstrated that intracellular kinase pathways can interact with and directly influence the Smad-signaling pathways [29, 55, 56]. Enhancement of Smad signaling via the MEK1/2/ERK pathway has been observed in glomerular mesangial cells [29], while MEK1/2/ERK signaling exerts an inhibitory...
effect on Smad activity in epithelial cells [56]. The variety of different responses reported suggests that interactions between these pathways take place in a cell-type-specific manner. Our data shows that inhibition of PI3K and MEK1/2/ERK signaling in a glial cell line partially blocked BMP-dependent activity of both the SBE and GFAP promoters, suggesting that the actions of these kinase pathways regulate gene activity in a cell-type-specific manner.

In contrast to the partial effects of PI3K and MEK1/2/ERK kinase inhibition at both promoters, abolishing Smad signaling completely blocked BMP-dependent activity of the SBE promoter while only partially inhibiting GFAP promoter activity. This is consistent with a scenario in which Smad signaling is modulated by these kinase pathways, promoting activation at the Smad-dependent SBE promoter and, to a lesser extent, at the partially Smad-regulated GFAP promoter. One way that the PI3K and MEK1/2/ERK pathways could act to globally modulate the actions of Smads at the SBE and GFAP promoters is by regulating Smad activation or translocation. We provide evidence that inhibition of the PI3K and MEK1/2/ERK pathways affects the level of cytosolic phosphorylated Smads following BMP treatment, suggesting that these kinases normally promote Smad phosphorylation upon BMP receptor binding. Interestingly, kinase inhibition did not affect the level of nuclear-localized phospho-Smad following a 30-min treatment with BMP2. This finding raises the possibility that the PI3K and MEK1/2/ERK pathways also influence the dynamics of nuclear shuttling of phosphorylated Smads either by limiting nuclear translocation or promoting movement from the nucleus to the cytoplasm [47]. However, further studies are needed to determine the effects of kinase signaling on the timing of Smad transport and on the relative contributions of nuclear import and export.

Once in the nucleus, phosphorylated Smads could promote gene expression via direct binding to Smad-responsive promoter elements, indirect interactions with the promoter, or by induction of transcription factors that indirectly control gene expression. Loss of GFAP induction by BMP2 in cycloheximide-treated cells, along with the absence of identifiable Smad consensus sites, suggests that Smad-dependent induction involves additional gene products. We have shown that Sp1 and a number of immediate early genes are induced by BMP2, including components of the AP1 complex. This suggests future studies to determine whether PI3K and MEK1/2/ERK signaling contributes to the regulation of these genes, and led us to question whether these early BMP-inducible genes contribute to the regulation of GFAP promoter.

Mutational analysis of the Sp1 and AP1 sites within the GFAP promoter suggests that these regulators contribute to the regulation of basal and BMP2-induced activity of the GFAP promoter. The pattern of promoter activation for the Sp1 mutant suggests that, under control conditions, a transcriptional repressor binds at the Sp1 site and occludes binding of the AP1 activator complex. In the presence of BMP2, this repressor is partially displaced, possibly as a result of increased Sp1 expression. This permits induction of the gene via the binding of activator proteins to multiple sites that may include the adjacent AP1 site. When the Sp1 site is mutated, AP1 can bind under control conditions, resulting in a higher baseline level of promoter activity. Treatment with BMP2 leads to activation from the additional site(s), resulting in a further induction. This maximal induction is not entirely additive, resulting in a modest decrease in the fold induction, even though overall expression levels are higher. Mutation of the AP1 site does not significantly affect baseline control transcription since the site is normally occluded under these conditions. Following BMP2 treatment, there is a trend toward increased expression that does not reach significance, consistent with partial induction from the additional, non-AP1 site. In the double mutant, protein binding to the Sp1 site does not occlude the AP1 site, but the AP1 mutation prevents AP1 binding with the result of normal basal expression and BMP2 induction involving the additional sites. This model (fig. 8) is consistent with studies showing that transcriptional repressors regulate Sp1 promoter binding and activity during regulation of myogenic cell proliferation and motor neuron development [57, 58]. Together, these data begin to define complex regulatory interactions at the GFAP promoter in which competition for promoter binding by activators and repressors, and the action of multiple activator interactions dynamically regulate cell type-specific GFAP expression.

The idea that competition between promoter-binding factors can contribute to the regulation of cell-type-specific gene expression has been suggested for Smad regulation of neuron and glial development in the central nervous system [59] and is consistent with a previously identified role for Sp1 in regulating distinct steps in lineage commitment during glial differentiation [60, 61]. The presence of the occluded AP1 activator site as well as additional BMP-dependent sites in the GFAP promoter suggests that the expression of different activator and repres-
signor proteins in specific cells types at precise developmental stages could drive the expression of lineage-specific patterns of gene expression during nervous system development. This could result in a cell type specificity of BMP action during the differentiation and maturation of distinct PNS lineages.

Acknowledgements

We thank Wyeth Pharmaceuticals for providing recombinant BMP2 and Tatiana Pozharskaya for technical assistance. This work was supported by NIH HD042716 to S.J.B., NIH F31 NS48661 to J.J.D., and by a grant for Core Facilities for Neuroscience at Brandeis P30 NS45713.

References


43 Feig LA, Cooper GM: Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GD. Mol Cell Biol 1988;8:3235–3243.


46 Lo LC, Birren SJ, Anderson DJ: V-myc im-...